Recombinant Human IGF-I/IGF-1 GMP Protein, CF GMP Best Seller
R&D Systems, part of Bio-Techne | Catalog # 291-GMP
Animal-Free
Key Product Details
Product Specifications
Source
E. coli-derived human IGF-I/IGF-1 protein
Gly49-Ala118
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.
Gly49-Ala118
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.
Purity
>97%, by SDS-PAGE with silver staining, under reducing conditions.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Gly-Pro-Glu-Thr-Leu-(Cys)-Gly-Ala-Glu-Leu
Predicted Molecular Mass
7.6 kDa
Activity
Measured in a serum-free cell proliferation assay using MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.
The ED50 for this effect is 0.3-1.5 ng/mL.
The specific activity of recombinant human IGF-I/IGF-1 is >1000 IU/mg, which is calibrated against the human IGF-I/IGF-1 WHO International Standard (NIBSC code: 91/554).
The ED50 for this effect is 0.3-1.5 ng/mL.
The specific activity of recombinant human IGF-I/IGF-1 is >1000 IU/mg, which is calibrated against the human IGF-I/IGF-1 WHO International Standard (NIBSC code: 91/554).
Host Cell Protein
<1.0 ng per µg of protein when tested by ELISA.
Mycoplasma
Negative for Mycoplasma.
Host Cell DNA
<0.0015 ng per µg of protein when tested by PCR.
Scientific Data Images for Recombinant Human IGF-I/IGF-1 GMP Protein, CF
Recombinant Human IGF-I/IGF-1 GMP Protein Bioactivity
GMP-grade Recombinant Human IGF-I/IGF-1 (Catalog # 291-GMP) stimulates cell proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner. The ED50 for this effect is 0.3‑1.5 ng/mL.
Recombinant Human IGF-I/IGF-1 GMP Protein SDS-PAGE
1 μg/lane of Recombinant Human GMP-grade IGF-I/IGF-1 (Catalog # 291-GMP) was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 8 kDa.
Recombinant Human IGF-I/IGF-1 GMP Protein Mass Spectrometry
MALDI-TOF analysis of GMP-grade Recombinant Human IGF-I/IGF-1 (Catalog # 291-GMP). The major peak at 7648 Da corresponds to the measured molecular weight of the intact protein. The calculated mass is 7655 Da.Formulation, Preparation and Storage
291-GMP
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IGF-I/IGF-1
Insulin-like growth factor 1 (IGF-1 or IGF-I), also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Human IGF-1 is synthesized as two precursor isoforms with N- and alternate C‑terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF‑1 is identical between isoforms and is generated by proteolytic removal of the N- and C‑terminal regions. Mature human IGF-1 shares 94% and 96% aa sequence identity with mouse and rat IGF-1, respectively (2), and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF2. Circulating IGF-1 is produced by hepatocytes, while local IGF-1 is produced by many other tissues in which it has paracrine effects (1). IGF-1 induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-1 regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4‑7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-1 binds IGF1R, IGF2R, and the insulin receptor, although its effects are mediated primarily by IGF1R (9). IGF-1 association with IGF binding proteins increases its plasma half‑life and modulates its interactions with receptors (10).
References
- Philippou, A. et al. (2007) In Vivo 21:45.
- Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
- Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
- Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
- Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
- Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
- Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
- Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
- LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
- Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.
Long Name
Insulin-like Growth Factor I/Insulin-like Growth Factor 1
Alternate Names
IGF-1, IGF1, IGFI, Somatomedin A, Somatomedin C
Gene Symbol
IGF1
UniProt
Additional IGF-I/IGF-1 Products
Product Documents for Recombinant Human IGF-I/IGF-1 GMP Protein, CF
Manufacturing Specifications
GMP ProteinsR&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.
R&D Systems' quality focus includes:
- Designed, manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
- Documented and controlled manufacturing process
- Control of documentation and process changes by QA
- Personnel training programs
- Raw material inspection and vendor qualification/monitoring program
- Validated equipment, processes and test methods
- Equipment calibration and maintenance schedules using a Regulatory Asset Manager
- Facility/Utilities maintenance, contamination controls, safety and pest control programs
- Material review process for variances
- Robust product stability program following relevant ICH guidelines
- N-terminal amino acid analysis
- SDS-PAGE purity analysis
- Molecular weight analysis via mass spectrometry
- Endotoxin assessment per USP <85> and Ph. Eur. 2.6.14 guidelines
- Bioassay analysis
- Microbial testing per USP <71> and Ph. Eur. 2.6.1 guidelines
- Host cell protein assessment
- Host cell DNA assessment
- Mycoplasma assessment
Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis and St. Paul, Minnesota USA.
R&D Systems sells GMP grade products for preclinical or clinical ex vivo use. They are not for in vivo use. Please read the following End User Terms prior to using this product.
Animal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.
Production
- All molecular biology procedures use animal-free media and dedicated labware.
- Dedicated fermentors are utilized in committed animal-free areas.
- Protein purification columns are animal-free.
- Bulk proteins are filtered using animal-free filters.
- Purified proteins are stored in animal-free containers.
Product Specific Notices for Recombinant Human IGF-I/IGF-1 GMP Protein, CF
Full terms and conditions of sale can be found online in the Protein Sciences Segment T&Cs at: Terms & Conditions.
For preclinical, or clinical ex vivo use
Loading...
Loading...
Loading...